Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HITM-SIR: Anti-CEA CAR-T + SIRT for Liver Metastases
NCT02416466Phase 1Completed
- Sponsor
- Roger Williams Medical Center
- Start
- Apr 2015
- Primary completion
- Nov 2016
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CEA-CART in liver metastases and Adenocarcinoma, sponsored by Roger Williams Medical Center. Primary endpoint: Number of Participants with Adverse Events at 14 weeks. Started Apr 2015; status: completed.
02
Drugs
CEA-CART
03
Conditions
liver metastasesAdenocarcinoma
Beyond the preview
Go deeper on NCT02416466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02416466.